MX2024014628A - Compuesto para inhibir o degradar bcl6 y uso de este en farmacia - Google Patents
Compuesto para inhibir o degradar bcl6 y uso de este en farmaciaInfo
- Publication number
- MX2024014628A MX2024014628A MX2024014628A MX2024014628A MX2024014628A MX 2024014628 A MX2024014628 A MX 2024014628A MX 2024014628 A MX2024014628 A MX 2024014628A MX 2024014628 A MX2024014628 A MX 2024014628A MX 2024014628 A MX2024014628 A MX 2024014628A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutics
- inhibiting
- compound
- bcl6
- degrading bcl6
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un compuesto representado por la fórmula general (I) o un estereoisómero, una forma deuterada, un solvato, un profármaco, un metabolito, una sal farmacéuticamente aceptable o un eutéctico del mismo, y un intermedio y una composición farmacéutica del mismo, y al uso del mismo en enfermedades relacionadas con Bcl6 tal como el cáncer. B-L-K (I).
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210619706 | 2022-06-02 | ||
| CN202210765237 | 2022-07-01 | ||
| CN202210793644 | 2022-07-08 | ||
| CN202211074021 | 2022-09-02 | ||
| CN202211391155 | 2022-11-11 | ||
| CN202310259014 | 2023-03-17 | ||
| PCT/CN2023/097939 WO2023232133A1 (zh) | 2022-06-02 | 2023-06-02 | 一种抑制或降解Bcl6的化合物及其在医药中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024014628A true MX2024014628A (es) | 2025-01-09 |
Family
ID=89025709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024014628A MX2024014628A (es) | 2022-06-02 | 2024-11-26 | Compuesto para inhibir o degradar bcl6 y uso de este en farmacia |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250333410A1 (es) |
| EP (1) | EP4534535A1 (es) |
| JP (1) | JP2025518252A (es) |
| KR (1) | KR20250020448A (es) |
| CN (1) | CN119343341A (es) |
| AU (1) | AU2023278399A1 (es) |
| CA (1) | CA3257736A1 (es) |
| MX (1) | MX2024014628A (es) |
| TW (1) | TW202404951A (es) |
| WO (1) | WO2023232133A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120813582A (zh) * | 2023-03-17 | 2025-10-17 | 西藏海思科制药有限公司 | 一种含氮三并环衍生物及其在医药上的应用 |
| WO2025104081A1 (en) * | 2023-11-13 | 2025-05-22 | Remynd N.V. | Triazole derivatives and their use in the treatment of neurodegenerative disorders |
| WO2025195363A1 (zh) * | 2024-03-18 | 2025-09-25 | 正大天晴药业集团股份有限公司 | 包含内酰胺结构的化合物 |
| CN120987969A (zh) * | 2024-05-21 | 2025-11-21 | 中国药科大学 | 一类蛋白靶向降解嵌合体及其用途 |
| WO2026013577A1 (en) * | 2024-07-10 | 2026-01-15 | Monte Rosa Therapeutics Ag | Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1 |
| WO2026021426A1 (zh) * | 2024-07-22 | 2026-01-29 | 江苏恒瑞医药股份有限公司 | 四环化合物、其制备方法及其在医药上的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012066488A2 (en) | 2010-11-17 | 2012-05-24 | Actelion Pharmaceuticals Ltd | Bridged spiro[2.4]heptane ester derivatives |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| JP6999688B2 (ja) * | 2016-12-13 | 2022-02-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｃｌ６阻害剤としての新規の６－アミノキノリノン化合物および誘導体 |
| IL273432B (en) | 2017-09-22 | 2022-09-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
| EP3728232B1 (en) | 2017-12-22 | 2023-08-30 | Ontario Institute for Cancer Research (OICR) | Novel quinolone compounds as inhibitors of the bcl6 btb domain protein-protein interaction and/or as bcl6 degraders |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| TW202102497A (zh) | 2019-03-29 | 2021-01-16 | 瑞典商阿斯特捷利康公司 | 化合物及它們在治療癌症中之用途 |
| WO2021023105A1 (zh) | 2019-08-02 | 2021-02-11 | 百济神州有限公司 | 咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物作为tlr8激动剂 |
| CN112538083B (zh) | 2019-09-23 | 2023-04-28 | 华东师范大学 | 一类靶向bcl6的芳香环并五元芳杂环类小分子有机化合物及其衍生物及其应用 |
| WO2021058017A1 (en) | 2019-09-29 | 2021-04-01 | Beigene, Ltd. | Degradation of androgen receptor (ar) by conjugation of ar antagonists with e3 ligase ligand and methods of use |
| CN115397821B (zh) | 2019-10-17 | 2024-09-03 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| AU2020397920A1 (en) | 2019-12-04 | 2022-06-16 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| US20230122219A1 (en) | 2020-02-03 | 2023-04-20 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| ES3048462T3 (en) | 2020-06-24 | 2025-12-10 | Celgene Corp | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| WO2022007866A1 (zh) | 2020-07-09 | 2022-01-13 | 深圳信立泰药业股份有限公司 | 并三环类衍生物、其制备方法及其在医药上的应用 |
| WO2022012622A1 (en) * | 2020-07-16 | 2022-01-20 | Beigene, Ltd. | Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use |
| US12122763B2 (en) | 2020-07-21 | 2024-10-22 | Ubix Therapeutics, Inc. | Substituted piperidines for androgen receptor degradation |
| WO2022109580A1 (en) | 2020-11-20 | 2022-05-27 | Janssen Pharmaceutica Nv | Inhibition of tyk2 dependent signaling pathways |
| US20240124465A1 (en) | 2020-12-18 | 2024-04-18 | St. Jude Children's Research Hospital | Molecules and methods related to treatment of disorders associated with jak-2 signaling dysfunction |
| CN116847848A (zh) | 2021-02-10 | 2023-10-03 | 百济神州有限公司 | Egfr降解剂和使用方法 |
| CR20230516A (es) | 2021-04-16 | 2024-01-23 | Arvinas Operations Inc | Moduladores de la proteólisis bcl6 y métodos de uso asociados |
| US20240279202A1 (en) | 2021-05-03 | 2024-08-22 | Nurix Therapeutics, Inc. | Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use |
| KR20240017814A (ko) | 2021-05-05 | 2024-02-08 | 바이오젠 엠에이 인코포레이티드 | 브루톤 티로신 키나제의 분해를 표적으로 하는 화합물 |
| US20250066326A1 (en) * | 2021-12-17 | 2025-02-27 | Dana-Farber Cancer Institute, Inc. | Bcl6 degraders and uses thereof |
| CN114591312B (zh) | 2022-03-17 | 2023-07-28 | 中国药科大学 | 一类砜及亚砜类化合物、其制备方法及医药用途 |
-
2023
- 2023-06-02 JP JP2024570845A patent/JP2025518252A/ja active Pending
- 2023-06-02 WO PCT/CN2023/097939 patent/WO2023232133A1/zh not_active Ceased
- 2023-06-02 EP EP23815310.0A patent/EP4534535A1/en active Pending
- 2023-06-02 CA CA3257736A patent/CA3257736A1/en active Pending
- 2023-06-02 AU AU2023278399A patent/AU2023278399A1/en active Pending
- 2023-06-02 CN CN202380043809.XA patent/CN119343341A/zh active Pending
- 2023-06-02 KR KR1020247040678A patent/KR20250020448A/ko active Pending
- 2023-06-02 TW TW112120663A patent/TW202404951A/zh unknown
- 2023-06-02 US US18/871,116 patent/US20250333410A1/en active Pending
-
2024
- 2024-11-26 MX MX2024014628A patent/MX2024014628A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119343341A (zh) | 2025-01-21 |
| WO2023232133A1 (zh) | 2023-12-07 |
| CA3257736A1 (en) | 2025-06-12 |
| TW202404951A (zh) | 2024-02-01 |
| EP4534535A1 (en) | 2025-04-09 |
| AU2023278399A1 (en) | 2024-12-19 |
| JP2025518252A (ja) | 2025-06-12 |
| KR20250020448A (ko) | 2025-02-11 |
| US20250333410A1 (en) | 2025-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024014628A (es) | Compuesto para inhibir o degradar bcl6 y uso de este en farmacia | |
| ZA202311035B (en) | Phosphonyl derivative, and composition and pharmaceutical application thereof | |
| PH12022551454A1 (en) | Pyrazolyl derivatives useful as anti-cancer agents | |
| MX2024008426A (es) | Compuesto para inhibir y degradar irak4, y composiciónes farmacéuticas y aplicación farmacéutica del mismo. | |
| PH12022551585A1 (en) | Substituted tricyclic compounds | |
| MX2022013054A (es) | Derivados de imidazolidinona y uso medico de los mismos. | |
| SA521422143B1 (ar) | 15-pgdh مثبط | |
| MX2021003739A (es) | Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos. | |
| ZA202206481B (en) | Amide derivative and preparation method therefore and use thereof in medicine | |
| ZA202405368B (en) | Camptothecin compound and conjugate thereof | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| MX2020000268A (es) | Agonista de fxr. | |
| MX2010007375A (es) | Nuevos derivados de lupano. | |
| MX2024000807A (es) | Inhibidor de aak1 y uso de este. | |
| TN2013000293A1 (en) | Derivatives of azaindazole or diazaindazole type as medicament | |
| PH12022551523A1 (en) | Cyclic compounds and methods of using same | |
| NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| MX2022006519A (es) | Medicamento conjugado con polietilenglicol, metodo de preparacion del mismo y uso del mismo. | |
| TN2013000257A1 (en) | Immunosuppressant formulations | |
| SE0400284D0 (sv) | Novel compounds | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| MX2021003662A (es) | Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo. | |
| MX2022006104A (es) | Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma. |